BCRX

BioCryst Pharmaceuticals, Inc.

6.29 USD
+0.01 (+0.16%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

BioCryst Pharmaceuticals, Inc. stock is up 41.99% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 54.84% of the previous 30 May’s closed higher than April. In the last 7 Unusual Options Trades, there were 2 PUTs, 5 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
06 May 15:37 21 Jun, 2024 5.00 PUT 1250 1100
07 May 17:03 20 Sep, 2024 8.00 PUT 100 216
15 May 14:02 17 Jan, 2025 8.00 CALL 299 1959
17 May 15:05 17 Jan, 2025 8.00 CALL 1000 2348
17 May 15:06 17 Jan, 2025 8.00 CALL 889 2348
17 May 15:08 17 Jan, 2025 7.00 CALL 953 118
17 May 15:10 17 Jan, 2025 7.00 CALL 900 118

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases. Galidesivir, a RNA dependent-RNA polymerase inhibitor, is in clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola,

  • JP Morgan
    Tue May 7, 11:28
    buy
    confirm
  • HC Wainwright & Co.
    Tue May 7, 06:14
    buy
    confirm
  • Needham
    Tue May 7, 05:32
    buy
    confirm